[Etretinate (Ro 10-9359, Tigason) and CCNU (1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea) and bleomycin versus CCNU and bleomycin in the treatment of advanced squamous cell carcinoma of the bronchus (Working group on Internal Medicine Oncology Study BS1/78)].
Forty-six evaluable patients with advanced squamous cell carcinoma of the lung were treated in a randomized fashion with either etretinate, CCNU and bleomycin in combination (ECB) or with CCNU and bleomycin (CB). There were no complete and no partial responses. Minor responses occurred in 5 patients (24%) with ECB and in 3 patients (12%) with CB independently of histological grade. No change was observed in 9 patients (43%) with ECB and in 13 patients (52%) with CB. There was no survival difference between the two groups. Reversible side-effects of skin and mucous membranes were more frequent under ECB. The antitumor efficacy of CB is marginal and could not be improved by the addition of the vitamin-A-derivative etretinate.
D000328:Adult; D000368:Aged; D001761:Bleomycin / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005050:Etretinate / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000008:administration & dosage*; D011379:Prognosis; D014212:Tretinoin / Q000031:analogs & derivatives*
D009607:Nitrosourea Compounds; D001761:Bleomycin; D014212:Tretinoin; D005050:Etretinate; D008130:Lomustine
Etretinat (Ro 10-9359, Tigason) + CCNU (1-(2-chloroathyl)-3-cyclohexyl-1-nitrosourea) + Bleomycin versus CCNU + Bleomycin in der Behandlung des fortgeschrittenen Plattenepithel-Karzinoms des Bronchus (AIO-Studie BS1/78).